PCI Biotech, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. Its PCI technology induces light-triggered endosomal release, which enhances various therapeutic modalities, such as small molecules, vaccines, and nucleic acids. The Company's lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a Phase I/II clinical study in bile duct cancer.